UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Raises Holdings in Savara Inc (NASDAQ:SVRA)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Savara Inc (NASDAQ:SVRA) by 24.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 156,983 shares of the company’s stock after buying an additional 31,168 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Savara were worth $482,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently bought and sold shares of SVRA. Woodline Partners LP raised its holdings in Savara by 16.6% during the fourth quarter. Woodline Partners LP now owns 2,686,938 shares of the company’s stock valued at $8,249,000 after acquiring an additional 381,743 shares during the period. Vestal Point Capital LP grew its position in Savara by 33.2% in the fourth quarter. Vestal Point Capital LP now owns 10,775,000 shares of the company’s stock worth $33,079,000 after acquiring an additional 2,685,000 shares in the last quarter. Squarepoint Ops LLC grew its position in Savara by 178.1% in the fourth quarter. Squarepoint Ops LLC now owns 122,635 shares of the company’s stock worth $376,000 after acquiring an additional 78,540 shares in the last quarter. Two Sigma Advisers LP grew its position in Savara by 34.8% in the fourth quarter. Two Sigma Advisers LP now owns 390,715 shares of the company’s stock worth $1,199,000 after acquiring an additional 100,800 shares in the last quarter. Finally, Two Sigma Investments LP grew its position in Savara by 19.4% in the fourth quarter. Two Sigma Investments LP now owns 785,477 shares of the company’s stock worth $2,411,000 after acquiring an additional 127,628 shares in the last quarter. 87.93% of the stock is owned by institutional investors.

Savara Trading Down 5.6%

Shares of Savara stock opened at $2.20 on Thursday. The firm has a 50-day simple moving average of $2.84 and a two-hundred day simple moving average of $2.90. The company has a market cap of $380.24 million, a P/E ratio of -5.12 and a beta of 0.32. Savara Inc has a fifty-two week low of $1.89 and a fifty-two week high of $5.11. The company has a debt-to-equity ratio of 0.13, a quick ratio of 17.70 and a current ratio of 17.70.

Savara (NASDAQ:SVRA) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($0.12) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.12). As a group, equities analysts predict that Savara Inc will post -0.45 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. Evercore ISI decreased their price objective on shares of Savara from $3.00 to $2.00 and set an “in-line” rating for the company in a research note on Wednesday, May 28th. Guggenheim reiterated a “buy” rating and issued a $8.00 price target (down previously from $9.00) on shares of Savara in a report on Wednesday, May 28th. Wells Fargo & Company reduced their price objective on shares of Savara from $8.00 to $7.00 and set an “overweight” rating for the company in a research note on Wednesday, May 28th. Finally, HC Wainwright downgraded shares of Savara from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $6.00 to $2.00 in a research note on Thursday, May 29th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $7.17.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.